Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update.

  title={Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update.},
  author={Sherif A Rezk and Xiaohui Zhao and Lawrence Martin Weiss},
  journal={Human pathology},
EBV-Associated Lymphoproliferative Disorders: Update in Classification.
The Impact of Epstein Barr-Virus on Therapeutic Options of Lymphoma
Future trends are thought to differ based on more better understanding of biology of EBV and to target such mechanisms that counteract or interfere with its pathogenesis including activation of apoptotic pathways or activating immunosuppression mechanisms.
EBV+ high‐grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi‐institutional study
It is unknown whether Epstein–Barr virus (EBV) infection can occur in high‐grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, also known as double‐ or triple‐hit lymphoma (DHL/THL).
An oncogenic Epstein Barr virus developing diseases and cancer in human
The present paper deals with the study of Epstein Barr virus causing several diseases including cancer in human, which ranges from infectious mononucleosis to the cancerous Burkitt’s lymphoma.
Chronic active Epstein-Barr virus infection progresses to aggressive NK cell leukemia with a poor prognosis.
The detailed diagnostic and differential diagnostic process of EBV infection was shown and a 20-year-old male patient with repeated infectious mononucleosis (IM)-like symptoms such as high fever, splenomegaly, lymphadenopathy for more than two years was reported.
Epstein - Barr virus association with plasma cell neoplasms.
Evaluated data shows that EBV was negative in all plasma cell myeloma cases in immunocompetent patients and has an overall low association with the different plasma cell neoplasms in the immunoccompetent setting.
Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1
This review summarizes the epidemiology of EBV-associated malignancies, their current standard-of-care, EBv-specific therapeutics in development, GPCRs and their druggability, and most importantly consolidates the findings of over 15 years of research on BILF1 in the context ofEBV-specific drug development.
Reactivation of Epstein–Barr Virus Presenting as Massive Splenomegaly after Initiation of Golimumab Treatment
A 71-year-old female with seronegative rheumatoid arthritis who presented with massive splenomegaly, pancytopenia, and positivization of antibodies against double-stranded deoxyribonucleic acid (dsDNA) after initiation of the anti-tumor necrosis factor (TNF) golimumab is reported.
The Morphologic Features of Primary Epstein-Barr Virus Infection in the Gastrointestinal Tract
It was found that there was no difference in pathologic findings in Immunocompetent and immunocompromised patients, which ranged from essentially subtle to severe mucosal architectural distortion with prominent lymphoid aggregates, and most cases showed either focal or diffuse lymphocytic infiltration.


Epstein–Barr virus-associated lymphomas
Recent developments in the understanding of EBV-associated lymphomagenesis in both the immunocompetent and Immunocompromised host are reviewed.
Extranodal NK/T cell lymphoma, nasal type.
Extranodal natural killer (NK)/T-cell lymphoma (ENKL) is a unique disease entity that is strongly associated with Epstein–Barr virus (EBV) infection. This disease is more common in Asia and Central
Epstein-Barr virus: the impact of scientific advances on clinical practice.
Recent acquired knowledge on the mechanisms of EBV persistence, immune control of primary and persistent infection, and disease pathogenesis is now being translated into the clinic with novel methods of diagnosis, prevention and treatment contributing to improved patient care.
Evidence for Early Infection of Nonneoplastic Natural Killer Cells by Epstein-Barr Virus
The data demonstrate that NK cells are natural targets of EBV and that infection of these cells is an early event observed during primary EBV infection.
EBV-associated lymphoproliferative disorders: classification and treatment.
Recent advances in EBV cell-based immunotherapy, which is beginning to show promise in the treatment of EBV-related disorders, are discussed.
The expanding spectrum of EBV+ lymphomas.
A series of Epstein-Barr virus–positive (EBV+) diffuse large B-cell lymphomas in young patients (median age 23 years) without known immunodeficiency are described.
Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review.
A large series of patients with this disease provided additional evidence that this neoplasia, with a median age of onset of 71 years, has the highest incidence in elderly patients aged >50 years, suggesting that this disease may be related to the immunological deterioration that occurs during the aging process.
B cells under influence: transformation of B cells by Epstein–Barr virus
  • R. Küppers
  • Medicine, Biology
    Nature Reviews Immunology
  • 2003
Intriguingly, the three main types of EBV-associated B-cell lymphoma — that is, Burkitt lymphoma, Hodgkin lymphoma and post-transplant lymphomas — seem to derive from germinal-centre B cells or atypical survivors of the germinalscentre reaction in most, if not all, cases, indicating that EBV -infected germinAL-cent centre B cells are at particular risk for malignant transformation.